Peers of Spyre Therapeutics Inc (SYRE)
Side-by-side comparison
Health Care · Biotechnology
Enterprise value divided by trailing twelve-month EBITDA. A popular valuation multiple that is capital-structure neutral.
Latest EV/EBITDA
-23.60x
As of Oct 9, 2026
Beyond EV/EBITDA, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.
| Date | EV/EBITDA |
|---|---|
| Oct 9, 2026 | -23.60x |
| Oct 8, 2026 | -21.71x |
| Oct 7, 2026 | -22.02x |
| Oct 6, 2026 | -21.78x |
| Oct 5, 2026 | -25.87x |
| Oct 2, 2026 | -26.02x |
| Oct 1, 2026 | -24.97x |
| Sep 30, 2026 | -24.67x |
EV/EBITDA = Enterprise Value / EBITDA (TTM). Enterprise Value = Market Cap + Total Debt − (Cash & Short-Term Investments + Long-Term Investments).
EV/EBITDA is widely used because it removes the effects of financing and non-cash accounting items.
Read the general EV/EBITDA definition, formula, and analyst usage guide.
EV/EBITDA guideInformational research only; not personalized advice. Values reflect the latest available data on Chartloom and may differ from other sources.
Side-by-side comparison